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The FHIT gene encompassing the most active common human chromosomal fragile region, FRA3B, was discovered in 1996 and
proposed as a tumour suppressor gene for important human cancers. Seven years and more than 350 reports later, early questions
concerning its tumour suppressor role have been answered. Recent studies on the role of Fhit loss in major types of human cancers
report association with high proliferative and low apoptotic indices, node positivity, loss of mismatch repair protein, likelihood of
progression and reduced survival.
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Soon after discovery, it was shown that the FRA3B/FHIT locus
frequently exhibits deletions in preneoplasias and cancers, Fhit
protein expression is lost or reduced in the majority of human
cancers, and the orthologous mouse Fhit locus is fragile and
exquisitely sensitive to carcinogen damage (Huebner et al, 1998;
Huebner and Croce, 2001).
In the last 3 years, more than 180 papers featuring Fhit have
appeared, as have publications on possible cancer association of
genes at other common fragile sites, and Fhit has been shown
unequivocally to act as a tumour suppressor. Fhit knockout mice
show increased susceptibility to spontaneous and induced
tumours, and oral gene therapy using adeno and adenoassociated
FHIT viruses prevents and reverses induced forestomach tumours
in Fhit þ/  mice (Fong et al, 2000; Dumon et al, 2001).
So what does this mean for diagnosis, prognosis and therapy of
human cancers? Here we review the types of cancers in which Fhit
loss is associated with specific clinical features, and consider the
importance of further investigation of consequences of Fhit loss in
these cancers (Figure 1).
UPPER GASTROINTESTINAL TRACT
Oral, oesophageal and gastric cancers are common in some Asian
countries and parts of Africa, and environmental agents, such as
alcohol and tobacco use, as well as certain dietary habits, are
suspected to play important roles.
In an early study using RNA extracted from oral carcinomas in
South Africa, FHIT transcription was examined by reverse
transcription of RNA and PCR amplification of the cDNA product
(RT–PCR) using primers within the FHIT open reading frame. In
a more recent study, these investigators (van Heerden et al, 2001)
compared the frequency of detection of FHIT aberrant expression
using the RT–PCR assay for mRNA aberration and analysis of
level of Fhit protein expression by immunohistochemical analysis
in tissue sections using several polyclonal anti-Fhit sera. The
findings were that 71% of the oral squamous cell carcinomas
(OSCCs) showed reduced or absent Fhit protein and half of the
cases with reduced Fhit showed aberrant RT–PCR products. Thus,
immunohistochemical analysis of Fhit expression is more sensitive
for the detection of alterations in expression (see Table 1 for a
summary).
Tanimoto et al (2000) had also studied OSCCs, as well as
premalignant lesions for aberrant FHIT RT–PCR products.
Evidence of aberrant transcripts was found in 53% of OSCCs
and in two of seven premalignant lesions, one of which was from a
patient who developed OSCC during follow-up. In a study of
OSCCs associated with betel and/or tobacco use (Chang et al,
2002), 28% of samples exhibited FHIT promoter methylation, and
36% of cancers and 50% of premalignant lesions showed aberrant
RT–PCR products, suggesting that FHIT aberration could be an
early event in oral carcinogenesis. Reduced Fhit expression was
observed in 41% of OSCCs. To determine the role of FHIT in
tongue cancers, Fhit expression was studied by immunohisto-
chemistry in sections from 41 stage II–IV squamous cell tongue
carcinomas (Lee JI et al, 2001). Lost or decreased Fhit expression
was demonstrated in 68% of tumours, especially in poorly
differentiated areas. Patients whose tumours showed low or no
Fhit had significantly shorter disease-free survival times than those
with high Fhit-expressing tumours. Thus, loss of Fhit could be an
independent prognostic indicator of clinical outcome for tongue
cancer patients. Consistently with these findings, Rosin et al (2002)
have shown that detection of allelic loss at the FHIT locus and/or
9p21 is a simple test for predicting a second oral malignancy at
previously treated oral cancer sites.
Similarly, frequent LOH at 3p has been observed in head and
neck squamous cell carcinoma (HNSCC). Mineta et al (2003)
examined 57 HNSCCs by immunohistochemistry, Western blot
and RT–PCR amplification for alterations in Fhit expression and
looked for association with clinicopathologic features. Low Fhit
expression was observed in 53% of cancers and correlated with
Ki-67 expression, an indicator of aggressive proliferation.
Moving down to the oesophagus, FHIT LOH and Fhit expression
were studied in precarcinomatous lesions and carcinoma. Primary
tumours (76%) showed LOH encompassing FHIT and 70% were Received 12 January 2003; accepted 3 March 2003
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www.bjcancer.comTable 1 FHIT alterations in primary cancers: association with clinical features (2000–2003 update)
Site/tissue Alterations Correlations/conclusions References
Oral cavity LOH, aberrant RT–PCR in premalignant lesions, SCCs Tanimoto et al (2000)
Tongue cancer Fhit reduced/absent in 68% Predicts poor outcome Lee JI et al (2001)
Betel/ tobacco-associated 41% OSCCs reduced Fhit, aberrant RT-PCR in 50%
preinvasive lesions
Chang et al (2002)
OSCC 3p, 9p LOH in post-treatment premalignant lesions Predicts second oral malignancy Rosin et al (2002)
71% OSCCs reduced or absent Fhit van Heerden et al
(2001)
HNSCC Fhit low in 53% Correlated with high Ki67 Mineta et al (2003)
ESC FHIT LOH in 76%, Fhit low in 70%, 4loss in
tobacco/alcohol users
Fhit loss an early event Mori et al (2000)
LOH or aberrant RT–PCR in 77% Fhit a target of carcinogens Menin et al (2000)
Reduced/absent Fhit in 78% Not correlated with prognosis, smoking history;
associated with progression
Shimada et al (2000)
Fhit loss in 89% invasive, 68% CIS, 43% dysplasias Associated with prognosis; not with p53 expression,
clinicopathological features or apoptosis
Kitamura et al (2001)
Lung/ head and neck Most showed Fhit loss, low p21, increased cell
proliferation
Low Fhit correlated with low apoptosis, high
proliferation. HNSCC cases with low Fhit showed
shorter survival
Pavelic et al (2001)
NSCLC 52% Fhit negative Correlated with FHIT LOH, inversely with KRAS
mutation; not with clinical parameters
Geradts et al (2000)
FHIT allelic imbalance in 64% Association with p53 overexpression Garinis et al (2001)
Fhit reduced in 67% of asbestos exposed, 59% in
nonexposed
FHIT inactivation contributes to ca. development Pylkkanen et al (2002)
Breast cancer 25% bilateral cases showed concordant FHIT LOH Suggests role in bilateral breast cancers Kollias et al (2000)
FHIT LOH studied FHIT LOH correlated with ER, PR negativity,
high S-phase fraction, reduced survival;
60% increased risk of dying
Ingvarsson et al (2001)
Fhit low in 67%, promoter hypermethylated
in 48%
FHIT inactivated biallelically by LOH,
hypermethylation
Yang et al (2002)
Brca1 deficient Fhit low in B90% of cases BRCA1 pathway important in protecting FHIT
from damage
Turner et al (2002)
Gastric cancer Fhit reduced in 63% Alteration in FHIT can play an important role Lee SH et al (2001)
Fhit expressed in preneoplastic lesions Suggests role in late carcinogenesis Caselli et al (2001)
FHIT LOH in 89%; Fhit low in 78% Associated with positive node status; lack of
mismatch repair could promote FHIT alterations
Huiping et al (2002)
Colon adenomas Fhit low in 47% Fhit inversely correlated with
degree of dysplasia; altered
Fhit occurs early in CRC development
Morikawa et al (2000)
CRC Fhit reduced in 44% carcinomas,
few ACF and adenomas; reduced in
most metastatic lesions
Decreasing Fhit with decreasing
differentiation and in tumours with
metastasis; low Fhit associated with degree
of dysplasia
Hao et al (2000)
Aberrant RT–PCR in 52%; 46% FHIT
genomic alteration
No correlation with clinicopathologic characteristics Luceri et al (2000)
50% positive for Fhit; Msh2 loss
correlated with Fhit loss
Fhit loss correlated with progression;
mismatch repair important in stability of
FHIT
Mori et al (2001)
Fhit loss in B18% well, moderately
differentiated, 81% of poorly diff.
ca. Loss of Mlh1 in 40%
Fhit loss associated with advanced
ca. and absence of Mlh1;
not with p53 expression
Andachi et al (2002)
Fhit absence/reduction in poorly diff. ca. Correlated with distant metastasis,
worse prognosis. Directly proportional
to apoptotic rates
Mady and Melhem
(2002)
Cervical cancer Fhit low in 71% invasive cancers,
52% HSILs associated with inv. ca.
Fhit loss more frequent in HSILs
associated with progression to inv. ca.
Connolly et al (2000)
Fhit reduced in 83% FHIT alterations important in cervical ca. Helland et al (2000)
FHIT gene altered in 67% FHIT inactivation involved in cervical ca. Herzog et al (2001)
Fhit low in 66% stage II–III ca. Poor prognostic factor Krivak et al (2001)
FHIT LOH frequent, occurred in
CIN synchronous with inv. ca.
Suggests essential role in clonal
selection and early cervical ca.
Guo et al (2001)
Aberrant RT–PCR in
20–30% CIN 2/3 lesions; Fhit loss rare
No association with HPV;
could be an independent risk factor
Terry et al (2002)
Fhit low in 50% CIN3, 78% MICA
lesions; 87% cases with low Fhit positive
for HPV16
Associated with HPV16 in
CIN1, 2, 3 and MICA; FHIT a cofactor
with HPV16
Butler et al (2002)
CIN¼cervical intraepithelial neoplasia; HSIL¼high-grade squamous intraepithelial lesion; MICA¼microinvasive carcinoma; OSCC¼oral squamous cell carcinoma;
ESC¼oesophageal squamous cell carcinoma; CRC¼colorectal carcinoma; ACF¼atypical crypt foci; NSCLC¼nonsmall cell lung carcinoma; IPF¼idiopathic pulmonary
fibrosis; HNSCC¼head and neck squamous cell carcinoma; ca.¼carcinoma.
Cancer and the FRA3B/FHIT fragile locus
K Huebner and CM Croce
1502
British Journal of Cancer (2003) 88(10), 1501–1506 & 2003 Cancer Research UKnegative for Fhit protein. Tumours of patients who were heavy
users of tobacco and alcohol showed significantly higher frequency
of loss of Fhit expression in this study. Noncancerous squamous
epithelia were mostly positive for Fhit, but five samples from heavy
tobacco/alcohol users were Fhit negative. In addition, most
carcinomas in situ (CIS), 50% of severe and moderate dysplasias
and 33% of mild dysplasia were Fhit negative, suggesting that Fhit
loss is an early event in ESC development (Mori et al, 2000).
Shimada et al evaluted the clinical impact of FHIT gene
alterations in 149 ESCs by immunohistochemical analysis, and
examined correlation with smoking history. Normal Fhit expres-
sion was observed in only 22% of cases, reduced expression in 45%
and absence of Fhit in 33%. Fhit was also markedly reduced in
muscle invasive tumours. This investigation did not find an
association of Fhit loss with prognosis or smoking history. In a
somewhat smaller study that included CIS and dysplasia in
sections of 75 ESCs, Fhit protein was reduced, relative to adjacent
normal mucosa, in 89% of invasive ESCs, 68% of CIS lesions and
43.5% of dysplastic lesions, so that Fhit loss was associated with
progressive ‘increases in severity of histopathological changes’
(Kitamura et al, 2001).
We believe that these findings concerning oral and oesphageal
cancers are very important. The treatment of these cancers can be
disfiguring and debilitating and recurrence is common. These
cancers are highly accessible for topical treatment using gene
therapy approaches to prevention and may be candidates for
future clinical trials, possibly using viral FHIT delivery.
The results of a number of recent reports of FHIT alterations in
gastric cancer are also briefly summarised in Table 1. To determine
if FHIT alterations are frequent in gastric carcinomas, Lee SH et al
(2001) examined FHIT LOH, aberrant RT–PCR products and Fhit
protein expression in 35 gastric adenocarcinomas. Aberrant
transcripts were detected in 57% and Fhit protein reduction in
63%. Caselli et al (2001) studied preneoplastic lesions in
histological samples of patients who developed gastric cancer
within 2 years and did not observe reduction or loss of Fhit
expression, whereas reduced or absent expression was observed in
61.5% of the cancers; complete Fhit loss was observed only in areas
of low differentiation. Huiping et al observed absence or reduction
of Fhit expression in 78% of gastric cancers and found an
association between abnormal Fhit expression and positive node
status. In summary, Fhit loss is frequent in gastric cancer, may not
be an early event and its prognostic value has not yet been
established.
COLON CANCER
When the FHIT locus was first discovered, we noted frequent
homozygous deletions in colon cancer cell lines and aberrant RT–
PCR products in primary colorectal cancers (Ohta et al, 1996).
Since then a number of investigators have examined the status of
the FHIT gene and protein in colon cancer (see Table 1 for a
summary). Hao et al (2000) examined aberrant crypt foci (ACF),
adenomas, primary colorectal carcinomas (CRCs) and metastatic
lesions for Fhit protein expression by immunohistochemistry. In
all, 44% of carcinomas showed marked loss or absence of
expression and the fraction of tumours with reduced expression
increased with decreasing differentiation and in tumours with
metastases (62 vs 38% in tumours without metastases); 12 out of 13
metastatic lesions showed reduced expression. Only a small
fraction of ACFs and adenomas showed reduced Fhit, but reduced
expression was strongly associated with degree of dysplasia. These
authors suggested that Fhit plays a role in development and
progression from the premalignant stage through metastasis.
Germline mutations in mismatch repair genes, usually MLH1
and MSH2, cause hereditary nonpolyposis colon cancer (HNPCC).
We had been interested in a possible connection between defective
mismatch repair and loss of Fhit expression because Fhit knockout
mice develop sebaceous tumours of the skin (Fong et al, 2000), as
do HNPCC carriers with Muir–Torre syndrome, involving
sebaceous tumours of the skin combined with colon tumours.
We also know that Msh2-deficient mouse cell lines show increased
chromosome fragility (Turner et al, 2002), suggesting that intact
mismatch repair systems are important for stability of fragile loci.
Consistently with this idea, several reports of increased Fhit loss in
Oral cavity, OSCC:
Fhit loss predicts
2nd malignancy,
poor outcome
Lung, NSCLC:
Fhit loss early,
associated with
low apoptosis and
high proliferation
Mammary gland, Brca.:
Fhit loss correlated
with negative ER, PR
high S phase, reduced
survival
Colon, CRC:
Fhit loss associated with
advanced Ca, metastasis
worse prognosis,
low apoptotic rate and
loss of mismatch repair
Head and neck, HNSCC:
Fhit loss correlates with
high proliferation,
shorter survival
Oesophagus, ESC:
Fhit loss an early event
Stomach, gastric ca.:
Fhit role late in
development, associated
with positive nodes,
loss of mismatch repair
promotes Fhit loss
Uterine cervix, Cca.:
Fhit absence a
marker of preinvasive
lesions with likelihood
of progression
Figure 1 Human tissues with especially vulnerable FHIT genes.
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(2001), in an analysis of 62 CRC cases by immunohistochemistry
for Fhit and Msh2 protein, found that Fhit loss correlated
significantly with progression of carcinoma, as well as with lymph
node metastasis, and loss of Msh2 correlated with loss of Fhit. Loss
of Fhit occurred in 50% of sporadic CRCs and was more frequent
in advanced cancers. It was concluded that mismatch repair
protein may be important in maintaining the integrity of the
common fragile locus within the FHIT gene. Similarly, Andachi
et al (2002) reported that reduced Fhit expression is associated
with mismatch repair deficiency in advanced colorectal carcinoma.
Interestingly, in a study of biopsies of periocular sebaceous
gland carcinomas, of patients with Muir–Torre syndrome,
Holbach et al (2002) determined that Fhit was detectable in the
one sebaceous gland carcinoma with microsatellite instability but
not in the five sebaceous carcinomas without microsatellite
instability. These authors made the intriguing suggestion that loss
of either Fhit or mismatch repair could contribute to the
development of sebaceous gland carcinoma in MTS.
Finally, in a study employing computerised image analysis to
quantitatively evaluate Fhit expression and apoptotic role in CRCs,
Mady and Melhem (2002) concluded that absence or reduction of
Fhit plays a role in the development of B23% of CRCs and was
directly correlated with the occurrence of distant metastases and
worse prognosis. Also, overexpression of Fhit was directly
proportional to the apoptotic rate.
Thus, the results of each study were consistent with the
conclusion that loss of Fhit protein expression, through damage
to the FRA3B fragile locus, has an important role in the
development of a significant fraction of colon cancers.
CERVICAL CANCER
Cervical cancer was the first to be assessed for Fhit protein
expression by immunohistochemistry and Fhit loss or reduction
was observed in B70% of cervical cancers, a loss that correlated
with the detection of aberrant FHIT RT–PCR amplification
products. In a follow-up study that included preinvasive lesions,
Connolly et al (2000) examined Fhit expression in 95 invasive
cervical carcinomas, 33 high-grade squamous intraepithelial
lesions (HSILs) associated with concurrent cancer, 38 HSILs
without associated cancer and 24 low-grade squamous intra-
epithelial (LSILs) lesions. Normal and LSIL samples showed
moderate to strong cytoplasmic staining while Fhit staining was
reduced or absent in 71% of invasive cancers, 52% of HSILs
associated with invasive cancer and only 21% of HSILs without
associated cancer. The conclusion was that loss of Fhit in HSILs
could serve as a marker of high-grade preinvasive lesions that are
likely to progress to invasive carcinoma.
In a study of 59 stage II–III tumours, absent or reduced Fhit
protein was observed in 66% (Krivak et al, 2001) and multivariate
analysis showed that reduced Fhit expression was a poor
prognostic factor. The 3-year survival rate for patients with Fhit-
positive tumours was 74 vs 37% for those with low Fhit-expressing
tumours.
Guo et al (2001) analysed intratumoural heterogeneity of
cervical cancers by studying 3p deletions and X-chromosome
inactivation patterns in multiple microdissected samples from
individual cancers. Allelic losses were frequently detected at 3p14.2
(FHIT), 3p21.3–21.2 and 3p24.2 markers and had occurred in CIN
lesions synchronous with invasive lesions. Although the study
involved normal and lesional DNAs from only 14 cervical cancers,
the authors concluded that the ‘findings suggest essential roles of
genes on these 3p loci, particularly the FHIT gene, in participating
in clonal selection and early development of cervical cancer’.
Butler et al (2002) also studied CIN and microinvasive
carcinoma (MICA) for expression of Fhit protein by immuno-
histochemistry and looked for association of Fhit loss with clinical
parameters, including high-risk HPV infection; 50% of CIN3 and
78% of MICA lesions showed reduction or absence of Fhit protein,
while CIN1 lesions showed moderate to strong Fhit expression. A
significant association was observed between loss of Fhit expres-
sion and HPV16 infection in the combined CIN and MICA lesions.
A number of reports have looked for a correlation of loss of Fhit
expression with presence of high-risk HPV genomes; some have
found such a correlation and others have not (see Table 1 for a
summary). Thus, this issue will need further, larger studies for
resolution.
LUNG CANCER
Owing to the connection between carcinogen exposure and Fhit
loss, Fhit involvement in lung cancer was studied rather
extensively early after discovery of the FHIT gene (reviewed in
Huebner and Croce, 2002). In the last 3 years, there have been
further reports on Fhit expression in lung cancer. Geradts et al
(2000) aimed to correlate loss of Fhit expression with molecular
genetic and clinical parameters in sections of 99 NSCLCs; 53% of
tumours lacked Fhit staining, a lack that correlated with LOH at
the FHIT locus. Fhit loss was as frequent as abnormalities of
expression of p53, RB and p16 and occurred independently of most
clinincal parameters and molecular abnormalities. Pavelic et al
(2001) also examined the status of the FHIT gene in lung cancer
and HNSCCs and compared it to expression of p21, frequency of
apoptosis and proliferation. Most malignant lung and HNSCC
lesions showed aberrant FHIT expression, reduced or absent p21
and increased cell proliferation. Fhit negativity tended to correlate
with a worse prognosis (22.46 months median survival vs 36.04
months for Fhit-positive cases) and the trend was significant for
HNSCCs (30.86 months median survival vs 64.04 months for Fhit-
positive cases, Po0.05). Thus, aberrant Fhit might be a prognostic
marker for lung cancer and HNSCC.
Garinis et al (2001) studied 67 NSCLCs and observed FHIT LOH
in 64%, for both squamous and adenocarcinomas. Allelic
imbalance at FHIT was 71% in stage I cancers, showing early
involvement. There was no association with kinetic parameters or
ploidy of tumours, but concurrent loss of Fhit and overexpression
of p53 was observed in 39%. Authors suggested that FHIT allele
losses could be the outcome of tobacco-induced mutagenesis.
Pylkkanen et al (2002) aimed to determine whether absent or
reduced Fhit or FHIT allele loss was associated with exposure to
lung carcinogens. Reduced Fhit expression was observed in 62% of
cases and was common in asbestos-exposed (67%) and non-
exposed cases (59%). FHIT LOH was increased in advanced
disease and in poorly differentiated tumours, supporting the
significance of FHIT inactivation in lung cancer development.
BREAST CANCER
The cytogenetics of breast cancer has recently been reviewed for
322 karyotypically abnormal samples from 256 patients (Teixeira
et al, 2002). ‘Interstitial deletions of the short arm of chromosome
3, with 3p14 as a minimally common deleted region, were
described as a recurrent change in breast carcinoma by Pandis
et aly. and have turned out to be the single most common
structural rearrangement’y. Also, it occurs usually as the sole
clonal abnormality and in benign proliferative disease of the
breast. Molecular studies have confirmed loss of 3p in breast
cancers, with loss at 3p13–14 having been reported in more than
40% of breast carcinomas (Teixeira et al, 2002). ‘A candidate
tumour suppressor gene in this region is FHIT and some studies
have shown that this gene is involved in breast cancery’.
Thus, although breast cancer cytogenetics is notoriously
complex, loss of 3p material, including the FHIT region, is an
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at least a portion of the FHIT gene was observed in a case of
bilaterial breast cancer, as were aberrant FHIT RT–PCR products
and reduced Fhit expression in several series of sporadic breast
cancers (reviewed in Huebner et al, 1998).
More recently, Kollias et al (2000) tested for concordant changes
in left and right breast cancers of young women with bilateral
cancer. Microsatellite markers were used to test for LOH at
candidate genes TP53, BRCA1, BRCA2, ATM and FHIT. Four cases
showed concordant loss of BRCA1 alleles in left and right cancers,
four for BRCA2, seven for ATM and four cases for FHIT,
suggesting possible roles for these tumour suppressor genes.
Several early studies of alterations at the FHIT locus in breast
cancer reported reduced expression of Fhit in B40–60% of
mammary carcinomas and an elevated frequency of loss in
BRCA2-linked breast carcinomas (Huebner and Croce, 2001).
The higher frequency of alteration of FRA3B and reduced
expression of Fhit in BRCA2-linked cancers was consistent with
the idea that loss of BRCA2 function affects stability of the FRA3B/
FHIT locus. This theme was pursued in a study of BRCA1-linked
breast cancers (Turner et al, 2002); breast tumours with
deleterious BRCA1 mutations were analysed for Fhit expression
by immunohistochemistry. Loss of Fhit expression was signifi-
cantly more frequent in the BRCA1 cancers compared with
sporadic breast tumours (9% Fhit positive vs 68% Fhit positive),
suggesting that the BRCA1 pathway is also important in protecting
the FRA3B/FHIT locus from damage. To further investigate the
relation between repair gene deficiencies and induction of fragile
sites in vitro, the frequency of aphidicolin-induced chromosome
gaps and breaks was analysed in PMS2-, BRCA1-, MSH2-, MLH1-,
FHIT- and TP53-deficient cell lines. Each repair-deficient cell line
showed elevated chromosome gaps and breaks, consistent with the
proposal that proteins involved in repair are important in
maintaining the integrity of common fragile regions (Turner
et al, 2002). Correspondingly, genes at common fragile sites may
sustain elevated levels of DNA damage in cells with deficient DNA
repair proteins such as those mutated in several familial cancer
syndromes.
Ingvarsson et al (2001) have examined the relation between
FHIT LOH and breast tumour progression. FHIT gene markers
were typed in 239 breast tumours and paired normal tissue, and
results assessed relative to clinicopathologic factors and LOH at
other regions. This study found that FHIT LOH was associated
with oestrogen and progesterone negativity, high S-phase fraction,
reduced patient survival and LOH at other chromosome regions.
Perhaps most interestingly, FHIT LOH resulted in a 60% increased
relative risk of death. The overall conclusion was that FHIT LOH
results in growth advantage of breast tumour cells, is associated
with an unstable genome and may be of prognostic value.
Similarly, Yang et al (2001), in a study of more than 160 breast
cancers occurring in Asian women, found reduction of Fhit
expression in 42%, and compared expression levels with
clinicopathological profiles and expression of other biological
markers. Reduced Fhit expression was significantly associated with
histological grade, high tumour proliferation, negative ER status
and p53 overexpression. Patients with tumours with loss of Fhit
expression tended to have poor survival. Results of these recent
breast cancer studies are summarised in Table 1.
CONCLUSION AND PERSPECTIVE
The data summarised indicate that the tumour suppressor gene,
FHIT, is altered in many human tumours, particularly in those
caused by environmental carcinogens, such as those present in
tobacco smoke. In many of these tumours, particularly in those
induced by tobacco or other environmental carcinogens, altera-
tions of FHIT occur very early during the multistep process of
carcinogenesis.
We have also shown that Fhit-negative cancer cells are very
sensitive to the expression of FHIT; for example, infection with
FHIT recombinant viruses (Huebner and Croce, 2001) can cause
regression and prevention of tumours in experimental animals.
Thus, it is logical to predict the development of a gene therapy
approach for the treatment and prevention of Fhit-negative human
cancers.
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